Body Mass Index influences Imatinib exposure in CML patients: evidence from TDM with adaptive dosing
Paul Maroselli, Joseph Ciccolini(Centre de Recherche en Cancérologie de Marseille), Régis Costello(Inserm), Geoffroy Venton(Inserm), Julien Colle(Inserm), Raphaëlle Fanciullino(Inserm), Pauline Roché(Hôpital de la Conception), Laure Farnault(Aix-Marseille Université)
Cited by 0
Related Papers
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
|Blood|2021|157
Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx
|Bulletin du Cancer|2018|108
Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors
|Blood Cancer Journal|2016|74
High incidence of atrial fibrillation in patients treated with ibrutinib
|Open Heart|2019|72